

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Entyvio (vedolizumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

	Prescriber Name:	
Patient Name:	Supervising Physician:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable)	:
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.		
Q1. What diagnosis is Entyvio being prescribed for (pick one)?		
☐ Moderate to severe ulcerative colitis		
☐ Moderate to severe Crohn's disease		
☐ Other		
Q2. Please provide ICD diagnosis code.		
Q3. Please indicate location of administration.		
□ Home		
☐ Long Term Care (LTC) facility		
☐ Physician office (drug from office stock - buy and bill)		
☐ Physician office (drug from pharmacy with a prescription	on)	
Q4. Is the prescriber a gastroenterologist?		
☐ Yes ☐ No		
Q5. Is the patient 18 years of age or older?		
☐ Yes ☐ No		



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Entyvio (vedolizumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name: Supervising Physician:		
Q6. Has the patient failed at least ONE anti-TNF agent (e.g. Cimzia, Humira, Remicade, or Simponi)? ☐ Yes ☐ No			
Q7. If the patient has NOT failed at least ONE anti-TNF agent (e.g. Cimzia, Humira, Remicade, or Simponi), please provide clinical justification as to why these agents would not be appropriate for this patient?			
Q8. Does the patient have history of progressive multifocal leukoencephalopathy (PML)?			
☐ Yes ☐ No			
Q9. Does the patient have history of other slow-virus infection [e.g. subacute sclerosing panencephalitis (SSPE), progressive rubella panencephalitis (PRP), HIV, AIDS, rabies]?			
☐ Yes ☐ No			
Q10. Does the patient have history of a medical condition that significantly compromises the immune system (e.g. leukemia, organ transplant)?			
☐ Yes ☐ No			
Q11. Additional Comments			
Prescriber Signature	Date		

□ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to the SWHP medical director at 1-888-316-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.



PRIOR AUTHORIZATION REQUEST FORM EOC ID: Entyvio (vedolizumab)

Phone: 800-728-7947

Litty vio (vedolizarilab)

Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

	Prescriber Name:
Patient Name:	Supervising Physician:

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document